Puma Biotechnology (PBYI) Interest & Investment Income (2012 - 2026)
Puma Biotechnology's (PBYI) quarterly Interest & Investment Income came in at $1.0 million in Q1 2026, down 8.99% YoY from $1.1 million in Q1 2025, and up 2.56% on a QoQ basis from $977000.0 in Q4 2025.
Puma Biotechnology (PBYI) Interest & Investment Income (2012 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 15 years of Interest & Investment Income data on file, last reported at $1.0 million in Q1 2026.
- Quarterly Interest & Investment Income fell 8.99% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 18.01% YoY) and the FY2025 annual result came in at $4.1 million, down 13.67% from the prior year.
- Interest & Investment Income grew to $1.0 million in Q1 2026, from $977000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $1.3 million in Q3 2024 to a low of $13000.0 in Q1 2022.
- A 5-year average of $777764.7 and a median of $956000.0 in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income slumped 46.28% — and 2023, when it jumped 4030.77%.
- Tracing PBYI's Interest & Investment Income over 5 years: stood at $519000.0 in 2022, then surged by 38.54% to $719000.0 in 2023, then soared by 70.51% to $1.2 million in 2024, then slipped by 20.31% to $977000.0 in 2025, then gained by 2.56% to $1.0 million in 2026.
- The last three Interest & Investment Income figures came in at $1.0 million (Q1 2026), $977000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 831,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 831,000.00 |
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | 977,000.00 |
| Sep 30, 2025 | 1.04 Mn |
| Jun 30, 2025 | 956,000.00 |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | 1.23 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Mar 31, 2024 | 972,000.00 |
| Dec 31, 2023 | 719,000.00 |
| Sep 30, 2023 | 689,000.00 |
| Jun 30, 2023 | 660,000.00 |
| Mar 31, 2023 | 537,000.00 |
| Dec 31, 2022 | 519,000.00 |
| Sep 30, 2022 | 216,000.00 |
| Jun 30, 2022 | 65,000.00 |
| Mar 31, 2022 | 13,000.00 |
| Dec 31, 2021 | 13,000.00 |
| Sep 30, 2021 | 13,000.00 |